CBIO

SQ Dalcinonacog alfa “DalcA”

Hemophilia B (rFIX)

Stage (next event)

Expected Date

Phase 2 Data

TBD

Catalyst Info & Data Links

MECHANISM OF ACTION

  • DalcA (CB2679d) is a recombinant, or lab-made clotting factor IX designed to serve as a prophylactic therapy to prevent or lessen bleedings in people with hemophilia B. It was specifically engineered to have a 22‐fold greater potency and a longer half‐life compared with the natural version of factor IX.(SOURCE)

Updated by JM 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

CBIO 1st Efficacy Results For MarzAA In HemA This Week

Synthetic Biologics Reports Positive Ph2b Data for SYN-004

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon